# Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

> **NCT05989425** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 32 (estimated)

## Conditions studied

- Differentiated Thyroid Cancer

## Interventions

- **DRUG:** surufatinib

## Key facts

- **NCT ID:** NCT05989425
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-04
- **Primary completion:** 2026-08-04
- **Final completion:** 2026-08-04
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05989425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05989425, "Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05989425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*